Patents Assigned to Synlogic Operating Company, Inc.
  • ENGINEERED MICROORGANISMS
    Publication number: 20240110191
    Abstract: The present invention relates to engineered microorganisms, wherein the engineered microorganisms comprise a therapeutic molecule and a modified pks island.
    Type: Application
    Filed: December 2, 2021
    Publication date: April 4, 2024
    Applicant: Synlogic Operating Company, Inc.
    Inventors: Michael James, Aida Kalantari, Tea Mirabella, Lauren Renaud, Lee Kristensen, Vincent Isabella
  • BACTERIA ENGINEERED TO TREAT DISEASES THAT BENEFIT FROM REDUCED GUT INFLAMMATION AND/OR TIGHTENED GUT MUCOSAL BARRIER
    Publication number: 20240110192
    Abstract: Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of treating or preventing autoimmune disorders, inhibiting inflammatory mechanisms in the gut, and/or tightening gut mucosal barrier function are disclosed.
    Type: Application
    Filed: May 10, 2023
    Publication date: April 4, 2024
    Applicant: Synlogic Operating Company, Inc.
    Inventors: Dean Falb, Vincent M. Isabella, Jonathan W. Kotula, Paul F. Miller, Yves Millet, Adam Fisher
  • Bacteria engineered to treat metabolic diseases
    Patent number: 11896627
    Abstract: Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of attenuating metabolic diseases are disclosed.
    Type: Grant
    Filed: January 26, 2022
    Date of Patent: February 13, 2024
    Assignee: Synlogic Operating Company, Inc.
    Inventors: Dean Falb, Vincent M. Isabella, Jonathan W. Kotula, Paul F. Miller, Sarah Elizabeth Rowe, Yves Millet, Adam B. Fisher
  • Bacteria engineered to treat a disease or disorder
    Patent number: 11883439
    Abstract: Genetically programmed microorganisms, such as bacteria, pharmaceutical compositions thereof, and methods of modulating and treating a disease and/or disorder are disclosed.
    Type: Grant
    Filed: December 17, 2020
    Date of Patent: January 30, 2024
    Assignee: Synlogic Operating Company, Inc.
    Inventors: Dean Falb, Paul F. Miller, Jonathan W. Kotula, Vincent M. Isabella, Suman Machinani, Adam B. Fisher, Yves Millet
  • Bacteria for the treatment of disorders
    Patent number: 11879123
    Abstract: Modified probiotics, pharmaceutical compositions thereof, and methods of modulating and treating disorders are disclosed.
    Type: Grant
    Filed: June 21, 2018
    Date of Patent: January 23, 2024
    Assignee: Synlogic Operating Company, Inc.
    Inventors: Dean Falb, Adam B. Fisher, Vincent M. Isabella, Jonathan W. Kotula, David Lubkowicz, Paul F. Miller, Yves Millet, Sarah Elizabeth Rowe
  • Recombinant bacteria engineered to treat diseases associated with methionine metabolism and methods of use thereof
    Patent number: 11859189
    Abstract: The present disclosure provides host cells, e.g., bacterial cells, that comprise a methionine decarboxylase enzyme for the treatment of diseases and disorders associated with methionine metabolism in a subject. The disclosure further provides pharmaceutical compositions and methods of treating disorders associated with methionine metabolism, such as homocystinuria.
    Type: Grant
    Filed: August 11, 2022
    Date of Patent: January 2, 2024
    Assignees: Synlogic Operating Company, Inc., Ginkgo Bioworks, Inc.
    Inventors: Dylan Alexander Carlin, Vincent M. Isabella, Jonathan McMurry, Theodore Carlton Moore, III, Mylene Perreault, Nathan Schmidt, Mark Simon
  • Bacteria engineered to treat diseases associated with hyperammonemia
    Patent number: 11845964
    Abstract: Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of modulating and treating disorders associated with hyperammonemia are disclosed.
    Type: Grant
    Filed: December 16, 2020
    Date of Patent: December 19, 2023
    Assignee: Synlogic Operating Company, Inc.
    Inventors: Dean Falb, Vincent M. Isabella, Jonathan W. Kotula, Paul F. Miller, Suman Machinani
  • Microorganisms engineered to reduce hyperphenylalaninemia
    Patent number: 11766463
    Abstract: Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of modulating and treating diseases associated with hyperphenylalaninemia are disclosed.
    Type: Grant
    Filed: June 3, 2022
    Date of Patent: September 26, 2023
    Assignee: Synlogic Operating Company, Inc.
    Inventors: Kristin Adolfsen, Per Greisen, Isolde Callihan, Adam Lawrence, James Spoonamore, Jay Konieczka
  • Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells
    Patent number: 11723932
    Abstract: Genetically programmed microorganisms, such as bacteria or virus, pharmaceutical compositions thereof, and methods of modulating and treating cancers are disclosed.
    Type: Grant
    Filed: January 11, 2017
    Date of Patent: August 15, 2023
    Assignee: Synlogic Operating Company, Inc.
    Inventors: Dean Falb, Jonathan W. Kotula, Vincent M. Isabella, Paul F. Miller, Suman Machinani, Saurabh Saha, Adam B. Fisher, Yves Millet, Ning Li
  • Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier
    Patent number: 11685925
    Abstract: Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of treating or preventing autoimmune disorders, inhibiting inflammatory mechanisms in the gut, and/or tightening gut mucosal barrier function are disclosed.
    Type: Grant
    Filed: September 8, 2016
    Date of Patent: June 27, 2023
    Assignee: Synlogic Operating Company, Inc.
    Inventors: Dean Falb, Vincent M. Isabella, Jonathan W. Kotula, Paul F. Miller, Yves Millet, Adam Fisher
  • Bacteria engineered to reduce hyperphenylalaninemia
    Patent number: 11618894
    Abstract: Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of modulating and treating diseases associated with hyperphenylalaninemia are disclosed.
    Type: Grant
    Filed: November 16, 2016
    Date of Patent: April 4, 2023
    Assignee: SYNLOGIC OPERATING COMPANY, INC.
    Inventors: Dean Falb, Vincent M. Isabella, Jonathan W. Kotula, Paul F. Miller, Sarah Rowe, Yves Millet
  • BIOSYNTHESIS OF ENZYMES FOR USE IN TREATMENT OF MAPLE SYRUP URINE DISEASE (MSUD)
    Publication number: 20220348933
    Abstract: Provided in this disclosure, in some embodiments, are methods and compositions for treating maple syrup urine disease (MSUD) and other conditions characterized by excessive branched-chain amino acids.
    Type: Application
    Filed: June 19, 2020
    Publication date: November 3, 2022
    Applicants: Ginkgo Bioworks, Inc., Synlogic Operating Company, Inc.
    Inventors: Patrick Boyle, Dylan Alexander Carlin, Rishi Jain, Ryan Putman, Laura Stone, Alex C. Tucker, Kolea Zimmerman
  • Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells
    Patent number: 11471494
    Abstract: Genetically programmed microorganisms, such as bacteria or virus, pharmaceutical compositions thereof, and methods of modulating and treating cancers are disclosed.
    Type: Grant
    Filed: January 5, 2018
    Date of Patent: October 18, 2022
    Assignee: Synlogic Operating Company, Inc.
    Inventors: Dean Falb, Jonathan W. Kotula, Vincent M. Isabella, Paul F. Miller, Suman Machinani, Saurabh Saha, Adam B. Fisher, Yves Millet, Ning Li, Jose M. Lora
  • Bacteria engineered to treat liver disease
    Patent number: 11439673
    Abstract: The disclosure provides genetically engineered bacteria that are capable of reducing excess ammonia and converting ammonia and/or nitrogen into alternate byproducts. The invention also provides pharmaceutical compositions comprising the genetically engineered bacteria, and methods of modulating and treating disorders associated with excess ammonia and inflammation in the gut and the liver, including, for example, hepatic encephalopathy, NASH/NAFLD, HCV, and Huntington's disease, in a subject, comprising administering the engineered bacterium to the subject.
    Type: Grant
    Filed: May 31, 2019
    Date of Patent: September 13, 2022
    Assignee: Synlogic Operating Company, Inc.
    Inventors: Paul F. Miller, Vincent M. Isabella, Dean Falb, Jonathan W. Kotula, Yossi Dagon
  • Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier
    Patent number: 11384359
    Abstract: Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of treating or preventing autoimmune disorders, inhibiting inflammatory mechanisms in the gut, and/or tightening gut mucosal barrier function are disclosed.
    Type: Grant
    Filed: September 8, 2016
    Date of Patent: July 12, 2022
    Assignee: SYNLOGIC OPERATING COMPANY, INC.
    Inventors: Dean Falb, Vincent M. Isabella, Jonathan W. Kotula, Paul F. Miller, Yves Millet, Adam Fisher
  • Bacteria engineered to treat metabolic diseases
    Patent number: 11291693
    Abstract: Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of attenuating metabolic diseases are disclosed.
    Type: Grant
    Filed: June 24, 2016
    Date of Patent: April 5, 2022
    Assignee: Synlogic Operating Company, Inc.
    Inventors: Dean Falb, Vincent M. Isabella, Jonathan W. Kotula, Paul F. Miller, Sarah Rowe, Yves Millet, Adam Fisher
  • Bacteria engineered to treat disorders in which oxalate is detrimental
    Patent number: 11273184
    Abstract: The present invention provides recombinant bacterial cells comprising at least one heterologous gene encoding at least one oxalate catabolism enzyme. In another aspect, the recombinant bacterial cells further comprise at least one heterologous gene encoding an importer of oxalate. The invention further provides pharmaceutical compositions comprising the recombinant bacteria, and methods for treating disorders in which oxalate is detrimental, such as hyperoxaluria, using the pharmaceutical compositions of the invention.
    Type: Grant
    Filed: August 31, 2016
    Date of Patent: March 15, 2022
    Assignee: Synlogic Operating Company, Inc.
    Inventors: Vincent Isabella, Dean Falb, Cami Leigh Anderson, Paul Miller, Yves Millet, Jonathan Kotula
  • Bacteria engineered to treat diseases associated with hyperammonemia
    Patent number: 11060073
    Abstract: Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of modulating and treating disorders associated with hyperammonemia are disclosed.
    Type: Grant
    Filed: May 18, 2017
    Date of Patent: July 13, 2021
    Assignee: Synlogic Operating Company, Inc.
    Inventors: Dean Falb, Vincent M Isabella, Jonathan W. Kotula, Paul F. Miller, Suman Machinani
  • Bacteria Engineered to Treat Diseases that Benefit from Reduced Gut Inflammation and/or Tighten Gut Mucosal Barrier
    Publication number: 20210095297
    Abstract: Genetically engineered bacteria, pharmaceutical compositions thereof, and methods of treating or preventing autoimmune disorders, inhibiting inflammatory mechanisms in the gut, and/or tightening gut mucosal barrier function are disclosed.
    Type: Application
    Filed: May 1, 2020
    Publication date: April 1, 2021
    Applicant: Synlogic Operating Company, Inc.
    Inventors: Dean Falb, Vincent M. Isabella, Jonathan W. Kotula, Paul F. Miller
  • Bacteria engineered to treat a disease or disorder
    Patent number: 10933102
    Abstract: Genetically programmed microorganisms, such as bacteria, pharmaceutical compositions thereof, and methods of modulating and treating a disease and/or disorder are disclosed.
    Type: Grant
    Filed: December 22, 2017
    Date of Patent: March 2, 2021
    Assignee: Synlogic Operating Company, Inc.
    Inventors: Dean Falb, Paul F. Miller, Jonathan W. Kotula, Vincent M. Isabella, Suman Machinani, Adam B. Fisher, Yves Millet